Dalton Bioanalytics

Executive Summary

Dalton Bioanalytics is a private multi-omics contract research organization (CRO) headquartered in Boston, MA, founded in 2019. The company provides advanced bioanalytical services to accelerate drug development and biomarker discovery for biopharma and biotech clients. Its core technology is the Omni-MS® platform, a proprietary LC-MS-based assay capable of profiling proteins, lipids, metabolites, electrolytes, drugs, and environmental chemicals from a single sample. This comprehensive approach positions Dalton as a key enabler for translational research, offering high-throughput, multi-plexed analysis that reduces sample requirements and turnaround times compared to traditional methods. By targeting the growing proteomics and metabolomics segments within the CRO market, Dalton addresses the increasing demand for integrated multi-omics solutions in precision medicine. Dalton Bioanalytics operates in a competitive landscape populated by larger CROs and emerging proteomics specialists. However, its Omni-MS® platform differentiation and focus on single-sample multi-omics may provide a competitive edge, particularly for complex biomarker discovery programs. The company is privately held with no disclosed funding history, suggesting potential for early-stage capital raises or strategic partnerships to scale commercial operations. Given its location in a major biotech hub and the rising importance of proteomics in drug R&D, Dalton is well-positioned for growth. Key near-term catalysts include securing a marquee pharmaceutical partnership, closing a Series A funding round to expand capacity, and achieving technical milestones that validate platform scalability.

Upcoming Catalysts (preview)

• Q1 2026Major Pharma Partnership for Omni-MS Platform40% success
• Q2 2026Series A Funding Round50% success
• Q3 2026Expansion into CNS or Oncology Biomarker Services30% success